12. References: Oncological Surgyery:
1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 2015; 33(6): 654-6
2. (NCCN Guidelines™). Cancer-associated venous thromboembolic disease Version
Uro-oncological surgeries:
3. Tikkinen KA, Cartwright R, Gould MK, Naspro R, Novara G, Sandset PM, Violette PD, Guyatt GH. Thromboprophylaxis in Urological Surgery
Immobilised patients:
4. ACCP 2016: Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2):
5. ISTH 2016: Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology Oct 1;17(10):e
6. ISTH 2013: Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis Jan 1;11(1):56-70.
Lung:
7. ISTH 2016: Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology Oct 1;17(10):e
Pancreas:
Multiple Myeloma:
8. NCCN 2017: Streiff MB, Holmstrom B, Bockenstedt PL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Cancer-Associated Venous Thromboembolic Disease, Version 1, 2017

13. References:
Routine thromboprophylaxis might be recommended in several other cancer patients with a higher risk of VTE:
1. Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update J Clin Oncol 2015; 33(6):
2. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907. doi: /blood
3. Cella CA, Di Minno G, Carlomagno C, et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. The oncologist Apr 19:theoncologist-2016.
4. Gerotziafas GT, Taher A, Abdel‐Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer‐Associated Thrombosis Study. The oncologist Oct 1;22(10):
Khorana Score:
1. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907. doi: /blood
ONKOTE Score:
1. Cella CA, Di Minno G, Carlomagno C, et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. The oncologist Apr 19:theoncologist-2016.
COMPASS Score:
1. Gerotziafas GT, Taher A, Abdel‐Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer‐Associated Thrombosis Study. The oncologist Oct 1;22(10):